CD38 and plasma cell myeloma: Remission-inducing therapy is an unmet need for patients with myeloma that is refractory to proteasome inhibitors, immunomodulatory agents, and an anti-CD38 monoclonal antibody, as well as to prior autologous stem cell transplantation.